Online inquiry

IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10558MR)

This product GTTS-WQ10558MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10558MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4240MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ9727MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ10850MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ12395MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ15828MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ9143MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ11944MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ3415MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW